Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 164
Filter
1.
Atherosclerosis ; 144(1): 177-84, 1999 May.
Article in English | MEDLINE | ID: mdl-10381291

ABSTRACT

HMG-CoA reductase inhibitors, such as pravastatin, are widely used as lipid lowering drugs in hypercholesterolemia. Pravastatin does not only reduce the atherogenic low density lipoprotein (LDL)-cholesterol, but is also increasing high density lipoprotein (HDL)-cholesterol. However, the mechanism leading to an increase of HDL are unclear. Therefore, the effects of pravastatin on the in vivo kinetics of apolipoprotein (apo) A-I were studied in six normolipidemic subjects and in a patient with coronary artery disease (CAD) utilizing stable isotope tracer techniques. Two turnover studies were performed. The first turnover study was carried out before any drug treatment, the second study after 6 weeks of 40 mg pravastatin/day. Three times deuterium labeled L-leucine (3D-leucine) was given as a primed bolus constant infusion (bolus: 1340 microg/kg; infusion: 22 microg/kg per h), and tracer uptake into HDL apoA-I was determined by gas chromatography (GC)-mass-spectrometry (MS). In the healthy subjects HDL-cholesterol increased by 13% and apoA-I increased by 12% under pravastatin treatment. The HDL in the CAD patient decreased by 3% and apoA-I increased by 2%. Prior to drug treatment the mean apoA-I fractional synthetic rate (FSR) was 0.194 per day (S.D. +/- 0.02) and apoA-I production rate (PR) was 10.8 mg/kg per day (S.D. +/- 2.1). The CAD patient had a FSR of 0.219 per day and a PR of 10.6 mg/kg per day. After treatment with pravastatin the mean apoA-I FSR was 0.204 per day (S.D. +/- 0.02) and apoA-I PR was 12.5 mg/kg per day (S.D. +/- 1.5) in the healthy subjects. Despite only minor changes of HDL and apoA-I in the CAD patient, there were significant changes of FSR (0.267 per day) and PR (13.1 mg/kg per day) with pravastatin treatment. The in vivo kinetic data demonstrate an increased FSR of apoA-I. The increase in apoA-I is due to an increased PR of apoA-I. This study demonstrates increased production of HDL apoA-I as the metabolic cause of the increase in HDL and apoA-I levels under inhibition of HMG-CoA reductase in man.


Subject(s)
Apolipoprotein A-I/drug effects , Coronary Disease/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Lipoproteins, HDL/drug effects , Pravastatin/administration & dosage , Adult , Apolipoprotein A-I/metabolism , Coronary Disease/blood , Female , Gas Chromatography-Mass Spectrometry , Humans , Lipoproteins, HDL/metabolism , Male , Reference Values , Software , Statistics, Nonparametric , Treatment Outcome
2.
Herz ; 21(4): 217-26, 1996 Aug.
Article in German | MEDLINE | ID: mdl-8805001

ABSTRACT

Numerous epidemiological studies have unequivocally proven a protection from the development of coronary heart disease by moderate long-lasting alcohol consumption. During the past 20 years studies in different ethnic groups starting from an American cohort and spanning to the recently performed analysis in the MONICA-project gave evidence for a decreased morbidity and mortality from coronary heart disease at 1 to 3 drinks a day when compared to total abstainers. A part of the protection is thought to be mediated through alcohol effects on plasma lipoprotein metabolism. Substantial increases in high-density lipoprotein cholesterol and its subfractions occur and are believed to be responsible for as much as half of the alcohol-mediated benefits. In addition, moderate decreases in low-density lipoprotein cholesterol and probably also in lipoprotein(a), established cardiovascular risk factors, may contribute accordingly. Furthermore, antioxidants like flavonoids and polyphenols found in red wines by protecting low density lipoproteins from oxidative modification may explain the "French paradox", the decreased incidence of coronary heart disease in France despite a high consumption of saturated fats. Also, alcoholic vasodilation, decreases in platelet aggregability, changes in prostacyclin/thromboxane ratios and increased fibrinolytic activities are to be considered as additional benefits caused by moderate alcohol consumption.


Subject(s)
Alcohol Drinking/physiopathology , Coronary Disease/blood , Lipids/blood , Myocardial Infarction/blood , Adult , Aged , Alcohol Drinking/mortality , Cause of Death , Coronary Disease/mortality , Coronary Disease/prevention & control , Female , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/prevention & control , Risk Factors , Survival Rate
3.
J Cardiovasc Pharmacol ; 27(4): 563-70, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8847874

ABSTRACT

In 12 weeks of active treatment, we compared the efficacy and safety of a new (micronized) formulation of fenofibrate (F) (200 mg/day) with that of simvastatin (S) (20 mg/day), an inhibitor of hydroxy-methyl-glutaryl coenzyme A (HMG-CoA)-reductase. Men and women with primary hyperlipoproteinemia (HLP) with low-density lipoprotein (LDL) cholesterol level 180-300 mg/dl and triglyceride level < 500 mg/dl had dietary treatment for 8 weeks, and 133 (2 of 3 type IIa, 1 of 3 type IIb HLP) were randomized. The decrease in total cholesterol differed between type IIa patients (F - 17.9 vs. S - 25.8%), the decrease in triglyceride levels between the type II b groups (F - 52.8 vs. S - 14%), whereas the degree of decrease in LDL cholesterol (F - 20.9 vs. S - 34.9%) differed among all patients. Despite the difference in LDL cholesterol decrease, no difference was noted in total apolipoprotein (apo) B lowering (F - 20.8 and S - 26.5%). Increases in high-density lipoprotein (HDL) cholesterol (F + 18.5 vs. S + 15%) differed specifically in type IIb patients (F + 33.6 vs. S + 11.4%), accompanied by a more pronounced increase in apo AI with fenofibrate (F + 10.5% vs. S no change). Improvement in the ratios of total cholesterol/HDL cholesterol and apo AI/apo B occurred similarly with both drugs. Only fenofibrate, not simvastatin, decreased both fibrinogen (-10.3 vs. + 3.6%) and uric acid (-25% vs. no change) in type IIa and type IIb patients. Safety parameters reflected drug-specific known side effects, underscoring the safety of both drugs in addition to their efficacy in lipid lowering. Besides its advantages in type IIb hyperlipidemia, micronized fenofibrate proved a potent drug in decreasing total and LDL cholesterol and in very effectively decreasing apo B-containing lipoproteins, which is a recommendation for its use in primary hypercholesterolemia.


Subject(s)
Anticholesteremic Agents/therapeutic use , Fenofibrate/therapeutic use , Hyperlipoproteinemia Type II/drug therapy , Hypolipidemic Agents/therapeutic use , Lovastatin/analogs & derivatives , Adolescent , Adult , Aged , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Female , Fenofibrate/adverse effects , Humans , Hyperlipoproteinemia Type II/blood , Lovastatin/adverse effects , Lovastatin/therapeutic use , Male , Middle Aged , Simvastatin , Triglycerides/blood
4.
Dtsch Med Wochenschr ; 120(10): 325-8, 1995 Mar 10.
Article in German | MEDLINE | ID: mdl-7875068

ABSTRACT

A now 24-year-old woman was found at the age of 2 years to have an hyperchylomicronaemia syndrome due to lipoprotein lipase deficiency: the triglyceride level was then 6000 mg/dl. But in subsequent years it had been reduced to between 550 and 2600 mg/dl by dieting. There were no xanthomas or abdominal symptoms during those years. When aged 20 years she was put on oral contraceptives (one-phase preparation: 0.03 mg ethinylestradiol and 0.075 gestodene). Six months later she had the first attack of severe necrotizing pancreatitis; three more attacks followed in the subsequent 6 months. All four attacks occurred during the drug-free period of the menstrual cycle. The relationship with contraceptive intake was not established until the fourth attack. The last acute pancreatitis (lipase 3283 U/l amylase 595 U/l, triglyceride 2400 mg/dl, WBC count 13,899/microliters; ultrasonography revealed fluid swelling and necrotic areas, especially around the splenic hilus) regressed within 5 days and has not recurred for 3 years after the patient stopped taking oral contraceptives. On a diet the triglyceride level has been around 880 mg/dl.


Subject(s)
Contraceptives, Oral/adverse effects , Ethinyl Estradiol/adverse effects , Hyperlipoproteinemia Type I/complications , Norpregnenes/adverse effects , Pancreatitis/chemically induced , Acute Disease , Adult , Female , Humans , Hyperlipoproteinemia Type I/diet therapy , Necrosis , Pancreatitis/pathology , Triglycerides/blood
5.
Exp Clin Endocrinol Diabetes ; 103(6): 391-7, 1995.
Article in English | MEDLINE | ID: mdl-8788313

ABSTRACT

Somatostatin (SRIF) is effective in the nonoperative management of a variety endocrine tumors. A potential role of SRIF for treatment of patients with primary hyperparathyroidism (pHPT) has been suggested. In a controlled, prospective, triple-blinded, randomized clinical trial, the somatostatin analogue octreotide (SMS 201-995, Sandostatin) was evaluated in 40 patients with well documented pHPT. Amongst other biochemical parameters, serum calcium and-phosphate and levels of parathyroid hormone, calcitonin, and osteocalcin as well as octreotide were assessed before and for 4 hours after a single iv. application of 200 micrograms ocreotide or placebo. SRIF-receptor autoradiography was performed in parathyroid tissue samples. Baseline values revealed a constellation of biochemical parameters typically found in pHPT. Following 200 micrograms octreotide, no significant changes in any of the biochemical parameters investigated for were observed. Multivariate analysis was performed to identify patient subpopulations in which any given combination of laboratory parameters changed in response to either drug or placebo. However, no 'responders' to octreotide were identified. 45% of patients receiving octreotide, reported side effects. Parathyroid tissue samples were negative for SRIF-receptor expression. It is concluded that a single dose iv. application of octreotide does not result in appreciable changes of biochemical parameters relevant in pHPT and carries a high rate of side effects. Furthermore, absence of SRIF-receptors in parathyroid tissue from patients with pHPT, together with lack of octreotide effects, suggests that somatostatin-analogues may not be effective in the non-operative therapy of pHPT.


Subject(s)
Hormones/therapeutic use , Hyperparathyroidism/drug therapy , Octreotide/therapeutic use , Adolescent , Adult , Aged , Autoradiography , Calcitonin/blood , Calcium/blood , Female , Humans , Hyperparathyroidism/metabolism , Hyperparathyroidism/pathology , Male , Middle Aged , Multivariate Analysis , Octreotide/blood , Osteocalcin/blood , Parathyroid Glands/chemistry , Parathyroid Glands/pathology , Parathyroid Hormone/blood , Phosphates/blood , Prospective Studies , Receptors, Somatostatin/analysis
6.
Dtsch Med Wochenschr ; 119(10): 327-31, 1994 Mar 11.
Article in German | MEDLINE | ID: mdl-8125035

ABSTRACT

Adrenomyeloneuropathy (AMN) is a "milder form" of adrenoleukodystrophy with a X-linked inheritance. Abnormal catabolism of the very long-chain fatty acids (VLCFA) results in Addison's disease and spastic paraparesis. The VLCFA concentration was measured in 23 of 26 patients with Addison's disease (mean age 48.5 [20-75] years) being treated at the University Hospital Marburg during May, 1991. The concentration was elevated in four of the 12 men with the disease, while it was within normal limits in the 11 women. Only two patients had paraparesis-like neurological deficits. This finding suggests that AMN is not as rare as has been supposed. It is recommended that the concentration of VLCFA be measured in all patients with Addison's disease, because an increase could have important consequences.


Subject(s)
Addison Disease/etiology , Adrenoleukodystrophy/complications , Adrenoleukodystrophy/genetics , Adrenoleukodystrophy/metabolism , Adult , Aged , Fatty Acids/blood , Fatty Acids/metabolism , Female , Humans , Male , Middle Aged , Muscle Spasticity/etiology , Paralysis/etiology , Sex Factors
7.
Pediatrics ; 93(2): 296-302, 1994 Feb.
Article in English | MEDLINE | ID: mdl-8121744

ABSTRACT

Apolipoprotein (apo)E polymorphism has been shown to be associated with different serum levels of cholesterol, apoB, and apoE. In clarifying the degree of influence of the apoE isoforms, investigations in an early stage of life are useful. The aim of the study was to investigate the plasma levels of apoB and apoA-I as structural proteins of low and high density lipoproteins, in relation to apoE phenotypes during the first year of life. Conclusions about the relationship between apoE phenotype and the development of the lipoprotein patterns can be drawn. The concentrations of apoB and apoA-I in capillary plasma as well as the apoE phenotype were estimated in 199 newborns (7 days old) and in follow-up investigations of a subgroup of 45 at 1, 4, 12, 24, and 52 weeks. The phenotype frequencies were as follows: 70% apoE 3/3, 16% apoE 3/4, 10% apoE 2/3, 2.5% apoE 2/2, and 1.5% apoE 4/2. The plasma concentrations of apoB and apoA-I in the newborns (7 days old) averaged 55% of the adult value and increased toward the end of the first year of life up to approximately 85%. The course of the plasma concentrations of apoB and apoA-I in relation to the apoE phenotype showed that, beginning at 24 weeks, the apoB levels were significantly lower for the phenotype E 2/2 and in tendency also for the phenotype E 2/3 in comparison with E 3/3. At the end of the first year of life, the apoB levels in infants with apoE phenotype 2/2 increased only by 50% and yielded 0.59 g/L.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Apolipoprotein A-I/analysis , Apolipoproteins B/analysis , Apolipoproteins E/genetics , Infant, Newborn/metabolism , Lipoproteins/metabolism , Polymorphism, Genetic , Female , Humans , Infant , Infant, Newborn/blood , Lipoproteins/blood , Longitudinal Studies , Male , Phenotype
8.
J Lipid Res ; 35(1): 153-8, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8138717

ABSTRACT

The influence of the genetic apolipoprotein (apo) E isoforms on human plasma lipoproteins is well established. There is, however, still a need for a phenotyping procedure applicable in laboratories not specialized in lipid research. To this end, we developed a rapid, automated electrophoresis method for apoE phenotyping. Either self-made or commercially available precasted gels can be used. Fresh or frozen samples corresponding to 0.1 microliter of plasma are applied automatically after lipid extraction in a urea-containing buffer onto the gel and isoelectric focusing is carried out for 45 min. Thereafter, apoE bands are precipitated by specific polyclonal antibodies and visualized by automated silver staining. The method is reliable, easily and quickly performed, and not restricted to specialized laboratories.


Subject(s)
Apolipoproteins E/isolation & purification , Isoelectric Focusing/methods , Apolipoproteins E/genetics , Blood Protein Electrophoresis/methods , Blood Protein Electrophoresis/statistics & numerical data , Evaluation Studies as Topic , Humans , Isoelectric Focusing/statistics & numerical data , Phenotype , Reproducibility of Results , Sensitivity and Specificity
9.
Clin Investig ; 71(2): 145-9, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8461626

ABSTRACT

Both hypercholesterolemia and hypertension are risk factors for atherosclerotic vascular disease, and elevated cholesterol levels occur more frequently than expected in patients with hypertension. Elevated levels of intermediate-density lipoproteins (IDL) and low-density lipoproteins (LDL) were shown to be atherogenic, and LDL, comprising the major cholesterol-carrying fraction in human plasma, are structurally related to lipoprotein (a)[Lp(a)], a further risk factor for atherosclerosis. In the present study we investigated 200 male employees (mean age 26 +/- 7 years) to determine whether the relationship of IDL and Lp(a) to systemic blood pressure is similar to the reported correlations between total and LDL cholesterol and systemic blood pressure. To this end blood pressure was measured several times in each individual, and lipids, lipoprotein-cholesterol, apolipoprotein B (apo B), and Lp(a) were determined in fasting serum. IDL cholesterol and apo B, the main protein component of IDL and LDL correlated with blood pressure. However, levels of Lp(a) correlated neither with systolic or diastolic blood pressure nor with lipoprotein cholesterol, body weight, or age. Although IDL and Lp(a) are considered lipoprotein risk factors for atherosclerosis, levels of Lp(a), unlike IDL, are not related to blood pressure, body weight, or age. Our data suggest different metabolic and pathophysiological mechanisms of the risk factors, IDL, LDL, and Lp(a).


Subject(s)
Blood Pressure , Lipoprotein(a)/blood , Lipoproteins, LDL/blood , Lipoproteins/blood , Adult , Body Weight , Cholesterol/blood , Cohort Studies , Humans , Lipoproteins, IDL , Male , Middle Aged , Reference Values , Triglycerides/blood
10.
Med Klin (Munich) ; 87(3): 113-7, 1992 Mar 15.
Article in German | MEDLINE | ID: mdl-1579086

ABSTRACT

The thyroid gland of 536 patients of a medical hospital in an iodine deficient area was investigated by ultrasound. According to the sonographic pattern and to the scintigraphic imaging the focal lesions were analysed as micro- or macrofollicular adenomas, autonomous adenomas, cysts and chalk. The prevalence of goitres was 37.7%. The prevalence of goitres was higher in women (45%) than in men (30%). Focal lesions could be observed in 27.6%, equally more often in women (36%) than in men (18.9%). The frequency of focal lesions increased with the age of the patients and with the volume of the thyroid gland. Autonomous adenomas were found three times more often in women than in men. Hyperthyroidism was only observed in patients with nodules larger than 4 cm in diameter. Sonographic screening examinations of the thyroid gland seem to be useful in all patients of a clinic of medicine because of the risk (25%) of iodine contamination by diagnostic measures.


Subject(s)
Goiter, Endemic/epidemiology , Thyroid Function Tests , Adolescent , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Germany/epidemiology , Goiter, Endemic/diagnostic imaging , Humans , Incidence , Male , Middle Aged , Ultrasonography
12.
Med Klin (Munich) ; 86(6): 294-6, 332, 1991 Jun 15.
Article in English | MEDLINE | ID: mdl-1653395

ABSTRACT

In ten patients with severe obstructive sleep apnea (OSA) profound changes in renal function could be demonstrated at night during nCPAP therapy. Natriuresis and diuresis decreased by about 50% while creatinine excretion rate and urinary osmolality did not change. We found parallel changes in the excretion of ANP's second messenger cyclic guanosine monophosphate (cGMP) in a dose-response-related manner to natriuresis respectively diuresis. These data are in agreement with recently demonstrated decrease of nocturnal plasma levels of atrial natriuretic peptide (ANP) during nCPAP therapy in apneic patients. This may be an indicator for an increased cardiac volume load during obstructive apnea. The decrease of diuresis, natriuresis and cGMP excretion demonstrate the beneficial effects of nCPAP treatment on the cardiovascular system. Therefore measurements of cGMP excretion may be a useful parameter to assess the cardiovascular function of apneic patients before and during treatment.


Subject(s)
Atrial Natriuretic Factor/blood , Cyclic GMP/urine , Diuresis/physiology , Natriuresis/physiology , Positive-Pressure Respiration , Sleep Apnea Syndromes/therapy , Adult , Aged , Aged, 80 and over , Circadian Rhythm/physiology , Female , Humans , Male , Middle Aged , Second Messenger Systems/physiology , Sleep Apnea Syndromes/urine
13.
Pneumologie ; 45 Suppl 1: 239-45, 1991 May.
Article in English | MEDLINE | ID: mdl-1650945

ABSTRACT

Recent studies about renal function and volume regulating hormones in obstructive sleep apnea (oSAS) indicate complex disturbances in volume homeostasis. Increased nocturnal secretion of atrial natriuretic peptide (ANP) and decreased renin secretion during apnea looks similar to a situation seen during hypervolemia or increased cardiac volume load. Increased venous return induced by pathologically high negative intrathoracic pressure during obstructive apnea may be the cause. Since during wakefulness no true hypervolemia is present, a "pseudohypervolemia" or "central hypervolemia" must exist caused by volume shift from the peripheral to the central compartment during apnea. Since volume homeostasis and blood pressure regulation are complexly connected the question arises whether disturbances in volume homeostasis play a role in the pathogenesis of arterial hypertension in sleep apnea. In a subgroup of hypertensive patients hypertension is salt-sensitive and volume dependent; it is called volume-expanded or low-renin hypertension. An inhibitor of the Na+/K(+)-ATPase acting via the digitalis receptor - called digitalis like factor (DLF) - is regarded as the causative agent for the development of hypertension in these cases. From this background, we were interested in the question whether DLF may be the linkage between disturbances in volume homeostasis and the pathogenesis of hypertension in sleep apnea. We could demonstrate a decrease of nocturnal urinary excretion of DLF during nasal continuous positive air pressure (nCPAP) therapy. Since a positive correlation between changes in diuresis respectively natriuresis and DLF excretion was found, we suggested DLF to be involved in changes of renal function in sleep apnea besides ANP. In 3 patients we measured nocturnal plasma levels of DLF and renin.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Atrial Natriuretic Factor/pharmacology , Digoxin , Plasma Volume/drug effects , Renin/pharmacology , Saponins , Sleep Apnea Syndromes/physiopathology , Blood Proteins/pharmacology , Cardenolides , Diuresis , Homeostasis , Humans , Kidney/drug effects , Kidney/physiopathology , Natriuresis , Plasma Volume/physiology , Sodium-Potassium-Exchanging ATPase/pharmacology
15.
Eur J Obstet Gynecol Reprod Biol ; 37(2): 155-62, 1990 Nov.
Article in English | MEDLINE | ID: mdl-2147014

ABSTRACT

Three different oral contraceptive preparations were studied before and after a 3 month treatment period with respect to their effects on plasma lipoprotein parameters. A total of 58 healthy women requesting oral contraception were randomly assigned to three groups. Each woman received either monophasic preparations containing ethinylestradiol and desogestrel (M-DG); ethinylestradiol and gestodene (M-GD); or a triphasic preparation of ethinylestradiol and levonorgestrel (T-LN). As has been reported in other studies, the concentrations of total plasma cholesterol and apolipoproteins B and A-IV did not change significantly in any group. HDL cholesterol, triglycerides, apolipoproteins A-I and A-II increased or tended to increase. Despite the effects of the three hormone preparations on these lipoprotein parameters, however, each led to a highly significant decrease in apolipoprotein E plasma levels. Considering the recently reported observations that oral contraceptives increase the hepatic uptake of cholesterol-rich remnants, this decrease in apo-E plasma levels may in women that take oral contraceptives be directly correlated with increased hepatic lipoprotein metabolism.


Subject(s)
Apolipoproteins E/blood , Contraceptives, Oral, Combined/pharmacology , Adolescent , Adult , Apolipoproteins A/blood , Apolipoproteins B/blood , Cholesterol/blood , Desogestrel , Ethinyl Estradiol/pharmacology , Female , Humans , Levonorgestrel , Liver/drug effects , Liver/metabolism , Norgestrel/pharmacology , Norpregnenes/pharmacology , Triglycerides/blood
16.
Electrophoresis ; 11(8): 627-30, 1990 Aug.
Article in English | MEDLINE | ID: mdl-2289461

ABSTRACT

On isoelectric focusing of human plasma and subsequent immunoblotting, using antii-human serum amyloid A (SAA) antibodies, a genetic variant of SAA was detected in a family of Turkish origin. All affected members of the family were apparent heterozygotes for the mutant protein, which underwent a charge shift of about one charge unit toward the anode. The variant is likely to be a mutant of the most prominent forms of SAA (SAA1 and SAA2, or SAA1 and SAA1 des Arg). The appearance of a genetic variant of two of the six reported SAA-isoforms in human plasma supports the concept of SAA proteins being products of different genes.


Subject(s)
Mutation , Serum Amyloid A Protein/genetics , Antibody Formation , Blotting, Western , Genetic Variation , Humans , Isoelectric Focusing , Pedigree , Sequence Homology, Nucleic Acid
17.
J Lipid Res ; 31(6): 1005-13, 1990 Jun.
Article in English | MEDLINE | ID: mdl-1973700

ABSTRACT

A family with three heterozygote and two homozygote carriers of the rare apolipoprotein E1 isoform was detected by isoelectric focusing. One of the homozygous patients had type III hyperlipidemia, while the other showed normolipemic dysbetalipoproteinemia. Restriction fragment length analysis as well as allele specific oligonucleotides were used to identify the structural alterations forming the abnormal epsilon 1 genotype. Comparison with the most common epsilon 3 allele showed that two base exchanges A for G in codon 127 and T for G in codon 158 (Asp for Gly and Cys for Arg, respectively) are responsible for the amino acid substitution which causes the charge shift observed in isoelectric focusing. The same defects have been described in the only previously characterized apoE1 (Weisgraber et al. 1984. J. Clin. Invest. 73: 1024-1033). In addition to the study by Weisgraber and coworkers, who reported on a heterozygous patient, we here describe the metabolic and clinical consequences of a homozygosity for this rare allele. Changes in lipoprotein metabolism, as well as in clinical phenotypes, were exactly identical to those seen in patients homozygous for the epsilon 2 allele, which has in common with the epsilon 1 allele the mutation in codon 158, but lacks the substitution in codon 127. In addition, lipoprotein profiles of the epsilon 3/epsilon 1 heterozygotes were indistinguishable from those of epsilon 3/epsilon 2 heterozygotes. Therefore, we conclude that the additional mutation in codon 127 that characterizes the epsilon 1 allele is of no functional importance in vivo.


Subject(s)
Apolipoproteins E/genetics , DNA/analysis , Hyperlipoproteinemia Type III/genetics , Lipoproteins/blood , Adolescent , Adult , Apolipoproteins E/blood , Base Sequence , Female , Humans , Hyperlipoproteinemia Type III/blood , Hyperlipoproteinemia Type III/metabolism , Male , Molecular Sequence Data , Oligonucleotide Probes , Polymorphism, Restriction Fragment Length
18.
Atherosclerosis ; 82(1-2): 97-103, 1990 May.
Article in English | MEDLINE | ID: mdl-2193640

ABSTRACT

Forty patients with NIDDM and hyperlipoproteinemia were selected for a 12-week double-blind placebo-controlled trial to study the effects of metformin on lipoprotein concentration and composition. A significant decrease occurred in VLDL-apo B and all lipid components of VLDL, indicating a decreased number of circulating VLDL, while LDL-apo B was unchanged. Moreover in VLDL the relative TG content increased, the cholesterol content decreased, while in LDL the TG content decreased and the cholesterol content increased, indicating a change in the particle distribution over the spectrum VLDL-IDL-LDL. The initially enhanced TG-content in HDL was reduced. While a reduction in VLDL is observed together with improving glucose control irrespective of the applied method, the observed compositional changes in VLDL and LDL have not been described before and seem to be metformin-specific.


Subject(s)
Apoproteins/blood , Diabetes Mellitus, Type 2/blood , Lipids/blood , Lipoproteins/blood , Metformin/pharmacology , Adult , Aged , Diabetes Mellitus, Type 2/complications , Double-Blind Method , Female , Humans , Hyperlipoproteinemias/blood , Hyperlipoproteinemias/complications , Male , Middle Aged , Randomized Controlled Trials as Topic
20.
Klin Wochenschr ; 68(2): 60-4, 1990 Jan 19.
Article in English | MEDLINE | ID: mdl-2319733

ABSTRACT

In the oral exocrine pancreatic function test using fluorescein dilaurate, this synthetic substrate attaches primarily to the triglyceride surfaces of the neutral lipids administered as part of the breakfast: these fluorescein dilaurate molecules cannot be attacked by cholesterol esterase. In the course of triglyceride saponification by lipase and colipase, however, the fluorescein dilaurate is liberated and hydrolyzed by cholesterol esterase. The pancreatic function test, therefore, measures the lipolytic activities not merely of cholesterol esterase, but indirectly of lipase, as well.


Subject(s)
Carboxylic Ester Hydrolases/physiology , Lipase/physiology , Lipolysis/physiology , Pancreas/enzymology , Pancreatic Function Tests/methods , Sterol Esterase/physiology , Bile Acids and Salts/physiology , Colipases/physiology , Dietary Fats/metabolism , Fluoresceins , Humans , Triglycerides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...